Drug research
200 mg pembrolizumab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as KEYTRUDA
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenNCT06699836 | CytoDyn, Inc. | Phase 2 | Active not recruiting | 2028-01Estimated |
Regulatory dates and decisions
| No regulatory events published here yet.Events appear after automated checks of their supporting sources. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |